Evidence map›Paper›PMID 26349840›Full record

ArticleCirculation. Cardiovascular quality and outcomes2015

Interpreting Hemoglobin A1C in Combination With Conventional Risk Factors for Prediction of Cardiovascular Risk.

Jamie A Jarmul, Michael Pignone, Mark J Pletcher

Open access · greenAbstract readMulticenter Study
In one paragraph

Article in Circulation. Cardiovascular quality and outcomes, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Association of glycated hemoglobin ACardiovascular diabetology · 2021
    Article
  5. Article
  6. Article
  7. Article
  8. Appropriateness of Using Tests for Blood Glucose and Diabetic Complications in Clinical Practice: Experiences in a Hospital in Thailand.Medical science monitor : international medical journal of experimental and clinical research · 2018
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jamie A Jarmul
Michael Pignone
Mark J Pletcher
University of North Carolina at Chapel Hill · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM008719 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DARVILLE, TONI, DESHMUKH, MOHANISH P · 1999 to 2023
$15.1M
Improving Cancer-Related Patient Decision MakingK05CA129166 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PIGNONE, MICHAEL P · 2008 to 2012
$765k
An Economic Framework for Evaluating Biomarkers Used to Target CVD PreventionR21HL112256 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PIGNONE, MICHAEL P, PLETCHER, MARK J · 2011 to 2012
$404k
NCI NIH HHS 5K05CA129166-05NCI NIH HHS K05 CA129166NHLBI NIH HHS R21 HL112256NIGMS NIH HHS T32 GM008719
6 · The paper itself

Abstract

backgroundHemoglobin A1C (HbA1C) is associated with increased risk of cardiovascular events, but its use for prediction of cardiovascular disease (CVD) events in combination with conventional risk factors has not been well defined. METHODS AND

resultsTo understand the effect of HbA1C on CVD risk in the context of other CVD risk factors, we analyzed HbA1C and other CVD risk factor measurements in 2000 individuals aged 40 to 79 years without pre-existing diabetes mellitus or CVD from the 2011 to 2012 National Health and Nutrition Examination Surveys survey. The resulting regression model was used to predict the HbA1C distribution based on individual patient characteristics. We then calculated post-test 10-year atherosclerotic CVD risk incorporating the actual versus predicted HbA1C, according to established methods, for a set of example scenarios. Age, sex, race/ethnicity, and traditional cardiovascular risk factors were significant predictors of HbA1C in our model, with the expected HbA1C distribution being significantly higher in non-Hispanic black, non-Hispanic Asian, and Hispanic individuals than that in non-Hispanic white/other individuals. Incorporating the expected HbA1C distribution into pretest atherosclerotic CVD risk has a modest effect on post-test atherosclerotic CVD risk. In the patient examples, we assessed that having an HbA1C of <5.7% reduced post-test risk by 0.4% to 2.0% points, whereas having an HbA1C of ≥6.5% increased post-test risk by 1.0% to 2.5% points, depending on the scenario. The post-test risk increase from having an HbA1C of ≥6.5% tends to approximate the risk increase from being 5 years older.

conclusionsHbA1C has modest effects on predicted atherosclerotic CVD risk when considered in the context of conventional risk factors.

Indexed as

EthnicityNutrition SurveysAdultAgedBiomarkersCardiovascular DiseasesDiabetes Mellitus, Type 2FemaleGlycated HemoglobinHumansMaleMiddle AgedMorbidityPrognosisRetrospective StudiesRisk AssessmentBiomarkersGlycated Hemoglobin

Identifiers

PMID26349840
PMCPMC4703493
OpenAlexW1917477082

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.